3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
2
Venous Thrombosis
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Irinotecan
5
Bevacizumab
5
Leucovorin
4
Fluorouracil
4
5,10-methylenetetrahydrofolic acid
3
Oxaliplatin
2
Levoleucovorin
2
Drug Therapy
2
Cetuximab
2
trametinib
1
spartalizumab
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
nazartinib
1
napabucasin
1
encorafenib
1
canakinumab
1
alectinib
1
Tinzaparin
1
Radiotherapy
1
Pemetrexed
1
Ocoxin
1
Mass Screening
1
KRN-330
1
Folfox protocol
1
Capecitabine
1
Artesunate
1
ABT-165
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Intestinal Neoplasms
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled